remaining questions for the treatment of patients with msi/dmmr mcrc with immunotherapy
Published 2 years ago • 110 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
1:11
checkmate-8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
0:43
immunotherapy in msi-h/dmmr mcrc: first-line options and dual checkpoint inhibition insights
-
4:32
immunotherapy regimens in dmmr/msi-high metastatic crc
-
5:44
a phase i/ii investigating the addition of io to the standard of care for patients with mss mcrc
-
1:23
the rationale for combining regorafenib with io to treat patients with refractory mss-crc
-
1:03
dr. nelson on the checkmate-142 trial in msi-h/dmmr mcrc
-
0:43
keynote-177 and checkmate 8hw: promising first-line immunotherapy for msi-h mcrc
-
4:00
immunotherapy combinations in msi and mss mcrc
-
9:25
debate: msi high colon cancer - immunotherapy
-
1:08
the role of neoadjuvant immunotherapy in msi-high gastric cancer
-
1:57
the emerging role of ctdna as a predicative marker in dmmr/msi-h colorectal cancer
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
6:56
keynote-177 results: pembrolizumab versus chemotherapy for patients with msi-h/dmmr colorectal c...
-
1:14
current and future trends in immunotherapy for msi-h colorectal cancer
-
1:35
dr. chu on the role of pembrolizumab in dmmr/msi-h mcrc
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
2:33
updated results for nivolumab in msi-h colorectal cancer
-
6:27
immunotherapy in msi-high pancreatic tumors